Eureka's ET140202 leads to tumor regression in Phase I for HCC

Eureka Therapeutics Inc. (Emeryville, Calif.) said ET140202 led to one case of complete tumor regression and two cases of partial tumor regression in six evaluable patients with alpha fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) in a Chinese Phase I trial. The company plans to start a U.S. Phase I trial of the T cell therapy next year.

The open-label, Chinese trial is enrolling AFP-positive HCC patients carrying at least one major histocompatibility complex class I A 2 (HLA-A2) allele who previously failed multiple lines of therapy to receive IV, intratumoral or intrahepatic artery infusions of ET140202. Eureka said the complete response occurred in a patient in the IV arm, with tumor regression observed in both the primary liver tumors and distal lung metastases after multiple doses of ET140202. Additionally, two patients had stable disease. ET140202 also reduced serum AFP levels in four patients...